Skip to content

US · ANTX · BIOTECHNOLOGY

AN2 Therapeutics, Inc. (ANTX) intrinsic value and stock valuation

$5.08as of 2026-11-21 · Mkt cap 210.33M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

AN2 Therapeutics, Inc. DCF and intrinsic value

InvestorsCraft values ANTX with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from ANTX’s statements →

AN2 Therapeutics, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Menlo Park, CA 94025 an2therapeutics.com

How the business is doing

Fiscal 2019–2025, USD

Revenue
$0.00
20192025
Net income
-$-35.17M
20192025
Free cash flow
-$-29.83M
20192025
Total equity
$53.1M+80.8% 5y CAGRd
20192025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2019–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-38.11M-$-54.55M-$-69.64M-$-42.26M-$-21.57M
Net income-$-35.17M-$-51.32M-$-64.73M-$-40.96M-$-21.54M
EPSd-$-1.16M-$-1.72M-$-2.74M-$-2.67M-$-1.15M
Operating cash flow-$-29.83M-$-49.26M-$-53.29M-$-33.46M-$-20.48M
Capital expenditure$0.00$0.00$0.00$0.00$0.00
Free cash flow-$-29.83M-$-49.26M-$-53.29M-$-33.46M-$-20.48M
Total assets$62M$92.1M$138.7M$102.6M$65.3M
Total debt$0.00$0.00$0.00$50K$0.00
Net debt-$-19.94M-$-21.35M-$-15.65M-$-27.17M-$-12.1M
Total equity$53.1M$81.9M$124.7M$95.4M$61.9M
Cash and short-term investments$58M$83.6M$107.3M$96.1M$58.6M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$0.00$0.00$0.00$80K$0.00
Gross profit$0.00$0.00$0.00-$-80K$0.00
Research and development expenses$24.8M$40.5M$54.9M$29.5M$16.9M
Selling, general and administrative expenses$13.3M$14.1M$14.8M$12.8M$4.67M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$38.1M$54.6M$69.6M$42.2M$21.6M
Cost and expenses$38.1M$54.6M$69.6M$42.3M$21.6M
Interest income$2.93M$5.47M$4.86M$1.35M$70K
Interest expense$0.00$0.00$0.00$510K$0.00
Depreciation and amortization$0.00$54.6M$69.6M$80K$0.00
Ebitda-$-35.17M$3.23M$4.9M-$-40.88M-$-21.54M
Operating income-$-38.11M-$-54.55M-$-69.64M-$-42.26M-$-21.57M
Total other income/expenses, net$2.94M$3.23M$4.9M$1.31M$30K
Income before tax-$-35.17M-$-51.32M-$-64.73M-$-40.96M-$-21.54M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-35.17M-$-51.32M-$-64.73M-$-40.96M-$-21.54M
Weighted average shares outstanding$30.2M$29.8M$23.6M$15.3M$18.7M
Weighted average diluted shares outstanding$30.2M$29.8M$23.6M$15.3M$18.7M
Balance sheet
20252024202320222021
Cash and short-term investments$58M$83.6M$107.3M$96.1M$58.6M
Net receivables$900K$300K$1.4M$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$59.9M$86.3M$110.5M$98.6M$60.1M
Property, plant and equipment, net$0.00$0.00$0.00$50K$0.00
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$2.01M$5.02M$27.2M$3.22M$3.49M
Total non-current assets$2.01M$5.83M$28.2M$3.94M$5.21M
Total assets$62M$92.1M$138.7M$102.6M$65.3M
Accounts payable$3.02M$3.32M$2.68M$2.12M$1.06M
Short-term debt$0.00$0.00$0.00$50K$0.00
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$8.72M$10.2M$14M$7.19M$3.4M
Long-term debt$0.00$0.00$0.00$0.00$0.00
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$170K$0.00$0.00$0.00$10K
Capital lease obligations$0.00$0.00$0.00$50K$0.00
Total liabilities$8.89M$10.2M$14M$7.19M$3.41M
Common stock$0.00$0.00$0.00$0.00$0.00
Retained earnings-$-240.95M-$-205.78M-$-154.46M-$-89.72M-$-47.38M
Accumulated other comprehensive income (loss)$60K$30K$280K-$-370K-$-30K
Total equity$53.1M$81.9M$124.7M$95.4M$61.9M
Total investments$40.1M$67.3M$118.8M$72.1M$49.9M
Total debt$0.00$0.00$0.00$50K$0.00
Net debt-$-19.94M-$-21.35M-$-15.65M-$-27.17M-$-12.1M
Cash flow statement
20252024202320222021
Net income-$-35.17M-$-51.32M-$-64.73M-$-40.96M-$-21.54M
Depreciation and amortization$0.00$0.00$0.00$0.00$0.00
Stock-based compensation$6.25M$8.34M$8.41M$4.39M$970K
Change in working capital$160K-$-3M$5.83M$3.72M$30K
Accounts receivable$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable-$-300K$640K$550K$2.5M$420K
Net cash provided by operating activities-$-29.83M-$-49.26M-$-53.29M-$-33.46M-$-20.48M
Investments in property, plant and equipment$0.00$0.00$0.00$0.00$0.00
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities$28.3M$54.6M-$-43.28M-$-21.77M-$-50.02M
Common stock issued$110K$370K$84.5M$70.4M$0.00
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$110K$370K$85M$70.4M$78.5M
Net change in cash-$-1.41M$5.7M-$-11.57M$15.1M$8.03M
Cash at end of period$19.9M$21.4M$15.7M$27.2M$12.1M
Operating cash flow-$-29.83M-$-49.26M-$-53.29M-$-33.46M-$-20.48M
Capital expenditure$0.00$0.00$0.00$0.00$0.00
Free cash flow-$-29.83M-$-49.26M-$-53.29M-$-33.46M-$-20.48M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About AN2 Therapeutics, Inc.

        AN2 Therapeutics, Inc. is a biopharmaceutical company currently in its clinical development phase, specializing in the creation of treatments for uncommon, long-term, and severe infectious conditions. A key focus of their pipeline is epetraborole, an investigational oral medication designed for once-daily administration to individuals battling chronic non-tuberculous mycobacterial lung disease. This enterprise was established in 2017 and operates from its headquarters situated in Menlo Park, California.

        CEO
        Eric E. Easom
        Employees
        21
        Beta
        -0.99

        Explore

        Frequently asked questions

        What is the intrinsic value of AN2 Therapeutics, Inc. (ANTX)?

        InvestorsCraft does not currently publish an intrinsic value for ANTX. How the IC value is calculated.

        Is ANTX undervalued?

        InvestorsCraft does not publish an undervaluation signal for ANTX at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.